DASH vs RYTM · P/E 76, rev $13.72B vs rev $130.1M
DoorDash, Inc. Class A Common Stock (DASH) versus Rhythm Pharmaceuticals Inc (RYTM) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Rhythm Pharmaceuticals Inc (RYTM) is a biotechnology company listed on NASDAQ.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported RYTM revenue for 2024-12-31 was $130.1M. Net income was -$260.6M. Revenue was up 68.1% from 2023-12-31 to 2024-12-31. RYTM currently screens at market cap $6.49B.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. RYTM currently screens at market cap $6.49B.
Not investment advice. Open the DASH and RYTM stock pages for the full models.
Not investment advice.